Harold J. Burstein, MD, PhD, FASCO (@DrHBurstein) ranks #12 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 22 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: NATALEE, VERITAC-2 (vepdegestrant), SERENA-6. CMS Open Payments lists no 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- Breast Cancer: US #12, Global #25 · 22 physicians engaged
- CMS Open Payments lists no 2025 general payments.
This Month
What Harold J. Burstein, MD, PhD, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Harold J. Burstein, MD, PhD, FASCO
Physicians who reposted Harold J. Burstein, MD, PhD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #12 | #25 | 22 | 27 | Full ranking |
Trials Harold J. Burstein, MD, PhD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| NATALEE | 1 | #10 of 46 | May 30, 2026 |
| VERITAC-2 (vepdegestrant) | 1 | #8 of 18 | May 1, 2026 |
| SERENA-6 | 1 | #8 of 39 | Apr 28, 2026 |
Harold J. Burstein, MD, PhD, FASCO on NATALEE
Reflecting the high risk study population, benefits of adjuvant ribo driven disproportionately by more proliferative breast cancer subsets in NATALEE trial. https://t.co/3kqQeh4oQn
Harold J. Burstein, MD, PhD, FASCO on VERITAC-2 (vepdegestrant)
Vepdegestrant approved, joining elacestrant and imlunestrant as monotherapy options for ESR1 mutated, advanced breast cancer. https://t.co/5CA9wqSjrN
Harold J. Burstein, MD, PhD, FASCO on SERENA-6
The @FDAOncology just posted materials for the ODAC on camizestrant in SERENA-6 trial. Key issue: PFS/PFS2. Should be a very interesting discussion. https://t.co/rLQkCe6d48
Harold J. Burstein, MD, PhD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Actually, not the right way to think about this. Mostly, it means the study was unnecessarily overpowered, even with the planned interim analysis. An important lesson for transformative drugs. https://t.co/yJ9YaWPkX9
The @FDA approves gedatolisib as 2nd line therapy in combo with fulvestrant in tumors w/o PIK3CA mutations. Median PFS F, 2.0m, F+G, 7.4m, F+G+palbo 9.3m. https://t.co/VPzVX3Wglb
Treatment algorithm in outline for ER+ MBC: Column A: endocrine agent (fulvestrant, oSERD, AI, tamoxifen) Column B: targeted agent (CDK46i, PIK3CAi) Choose one from column A and one from column B. Repeat with each line of treatment.
Updated financial take on Merck vaccine data in the @WSJ Link to article is free https://t.co/lqmFEU9wch https://t.co/mqt5kxFV59
An unusual 10 day span for a new drug with one approval requiring confirmation and a second study that is negative https://t.co/ajR1Bks4G2
Industry Payments
CMS Open Payments · 2025 general payments
$0 across 0 payments